Carsten Gründker Selected Research

Gonadotropin-Releasing Hormone (GnRH)

1/2021	Role of Gonadotropin-Releasing Hormone (GnRH) in Ovarian Cancer.
1/2021	The Role of Gonadotropin-Releasing Hormone (GnRH) in Endometrial Cancer.
1/2017	The Role of Gonadotropin-Releasing Hormone in Cancer Cell Proliferation and Metastasis.
6/2016	Invasion and increased expression of S100A4 and CYR61 in mesenchymal transformed breast cancer cells is downregulated by GnRH.
6/2014	Efficacy and safety of AEZS-108 (INN: zoptarelin doxorubicin acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: a multicenter phase II trial of the ago-study group (AGO GYN 5).
2/2014	Efficacy and safety of AEZS-108 (LHRH agonist linked to doxorubicin) in women with advanced or recurrent endometrial cancer expressing LHRH receptors: a multicenter phase 2 trial (AGO-GYN5).
1/2013	Starving tumors: inhibition of glycolysis reduces viability of human endometrial and ovarian cancer cells and enhances antitumor efficacy of GnRH receptor-targeted therapies.
12/2011	Agonists and antagonists of GnRH-I and -II reduce metastasis formation by triple-negative human breast cancer cells in vivo.
9/2011	Effective targeted chemotherapy using AEZS-108 (AN-152) for LHRH receptor-positive pancreatic cancers.
5/2011	Targeted chemotherapy for triple-negative breast cancers via LHRH receptor.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Carsten Gründker Research Topics

Disease

39	Neoplasms (Cancer) 12/2021 - 01/2002
28	Breast Neoplasms (Breast Cancer) 12/2021 - 10/2004
18	Ovarian Neoplasms (Ovarian Cancer) 01/2021 - 02/2002
13	Endometrial Neoplasms (Endometrial Cancer) 01/2021 - 01/2002
11	Triple Negative Breast Neoplasms 07/2019 - 01/2010
5	Neoplasm Metastasis (Metastasis) 01/2021 - 12/2011
3	Bone Resorption 09/2003 - 01/2002
2	Pancreatic Neoplasms (Pancreatic Cancer) 01/2017 - 09/2011
1	Endometrial Hyperplasia 01/2021
1	Glioblastoma (Glioblastoma Multiforme) 01/2017
1	Adenocarcinoma 09/2011

Drug/Important Bio-Agent (IBA)

33	Gonadotropin-Releasing Hormone (GnRH)FDA Link 01/2021 - 01/2002
22	LHRH Receptors (Gonadotropin-Releasing Hormone Receptor)IBA 01/2021 - 01/2002
11	lysine(6)-doxorubicin LHRHIBA 07/2019 - 09/2002
10	Estrogens (Estrogen)FDA Link 01/2021 - 01/2008
10	Doxorubicin (Adriamycin)FDA LinkGeneric 06/2014 - 05/2002
10	His(5)-Trp(7)-Tyr(8)- LHRHIBA 01/2013 - 03/2002
9	Triptorelin Pamoate (Trelstar)FDA Link 01/2008 - 02/2002
8	Estrogen ReceptorsIBA 12/2021 - 04/2008
7	Growth Factor ReceptorsIBA 01/2017 - 01/2002
6	Progesterone Receptors (Progesterone Receptor)IBA 01/2018 - 01/2010
5	Pharmaceutical PreparationsIBA 10/2020 - 01/2008
5	Protein Tyrosine PhosphatasesIBA 01/2017 - 01/2002
4	Tamoxifen FDA LinkGeneric 12/2021 - 11/2005
4	afimoxifene (hydroxytamoxifen)IBA 12/2021 - 10/2005
4	Caspase 3 (Caspase-3)IBA 05/2011 - 05/2004
4	cetrorelix (Cetrotide)FDA Link 07/2004 - 02/2002
3	Deoxyglucose (2 Deoxy D glucose)IBA 07/2019 - 01/2013
3	Estrogen Receptor Modulators (Antiestrogen)IBA 12/2014 - 04/2008
3	MelatoninIBA 04/2010 - 11/2005
3	Cytotoxins (Cytolysins)IBA 01/2009 - 05/2004
3	RANK LigandIBA 06/2008 - 01/2002
3	NF-kappa B (NF-kB)IBA 01/2008 - 01/2002
3	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 02/2007 - 01/2002
3	Oncogene Proteins (Oncogene Protein)IBA 02/2007 - 01/2002
2	Lactic Acid (Lactate)FDA LinkGeneric 12/2021 - 01/2020
2	Glucose (Dextrose)FDA LinkGeneric 12/2021 - 01/2020
2	Hormones (Hormone)IBA 12/2021 - 04/2010
2	GonadotropinsIBA 01/2021 - 11/2012
2	Small Interfering RNA (siRNA)IBA 12/2020 - 07/2012
2	Proteins (Proteins, Gene)FDA Link 01/2019 - 08/2009
2	Cysteine (L-Cysteine)FDA Link 01/2019 - 06/2016
2	Estrogen Receptor alphaIBA 01/2018 - 11/2004
2	resazurinIBA 04/2017 - 01/2013
2	Gefitinib (Iressa)FDA Link 02/2017 - 11/2012
2	Biological ProductsIBA 06/2016 - 11/2006
2	AntibodiesIBA 07/2015 - 02/2014
2	Protein Isoforms (Isoforms)IBA 07/2015 - 02/2014
2	human ERBB2 proteinIBA 02/2015 - 07/2012
2	human KISS1 proteinIBA 02/2014 - 12/2010
2	Messenger RNA (mRNA)IBA 07/2012 - 03/2002
2	DNA (Deoxyribonucleic Acid)IBA 12/2011 - 05/2002
2	ElementsIBA 04/2010 - 08/2009
2	Cyclic AMP Response Element-Binding Protein (Cyclic AMP-Responsive DNA-Binding Protein)IBA 04/2010 - 08/2009
2	Melatonin Receptors (Melatonin Receptor)IBA 04/2010 - 08/2009
2	OsteoprotegerinIBA 06/2008 - 09/2003
2	Estradiol (Delestrogen)FDA LinkGeneric 04/2007 - 11/2004
2	Epidermal Growth Factor (EGF)IBA 11/2006 - 10/2005
1	Selective Estrogen Receptor Modulators (SERM)IBA 12/2021
1	EnzymesIBA 12/2020
1	rho GTPase-activating proteinIBA 12/2020
1	GTP Phosphohydrolases (GTPases)IBA 12/2020
1	Zinc Finger E-box-Binding Homeobox 1IBA 10/2020
1	Connective Tissue Growth FactorIBA 10/2020
1	Protein-Lysine 6-Oxidase (Lysyl Oxidase)IBA 10/2020
1	betaIG-H3 protein (keratoepithelin)IBA 10/2020
1	ProteomeIBA 10/2020
1	Adenosine Triphosphate (ATP)IBA 07/2019
1	pegvisomant FDA LinkGeneric 06/2018
1	Somatotropin Receptors (Growth Hormone Receptor)IBA 06/2018
1	GTP-Binding Proteins (G-Protein)IBA 01/2018
1	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 01/2018
1	Metformin (Glucophage)FDA LinkGeneric 04/2017
1	Trastuzumab (Herceptin)FDA Link 02/2017
1	S100 Calcium-Binding Protein A4IBA 06/2016
1	Estriol (Epiestriol)IBA 12/2014
1	Topotecan (Hycamtin)FDA LinkGeneric 06/2014
1	PlatinumIBA 06/2014
1	taxaneIBA 06/2014
1	Acetates (Acetic Acid Esters)FDA Link 06/2014
1	liposomal doxorubicin (Doxil)FDA Link 06/2014
1	perifosineIBA 11/2012
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 07/2012
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 07/2011
1	Thrombospondin 1IBA 07/2011
1	Chemokine ReceptorsIBA 12/2010
1	Progestins (Progestagens)IBA 06/2010
1	salicylhydroxamic acid (SHAM)IBA 04/2010
1	p38 Mitogen-Activated Protein KinasesIBA 01/2010
1	Phosphotransferases (Kinase)IBA 08/2009
1	Mitogen-Activated Protein KinasesIBA 08/2009
1	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 04/2009
1	Plasminogen Activators (Plasminogen Activator)IBA 04/2009
1	Tissue Plasminogen Activator (Alteplase)FDA Link 04/2009

Therapy/Procedure

15	Therapeutics 12/2021 - 02/2005
8	Drug Therapy (Chemotherapy) 06/2018 - 09/2002
6	Aftercare (After-Treatment) 02/2017 - 09/2002
2	Radiotherapy 02/2014 - 04/2007
1	Intraperitoneal Injections 07/2011
1	Intravenous Administration 01/2009